Extrasystoles

Articolo redatto e revisionato del Dott. Luca Moretti

Extrasystoles are the occurrence of one or more cardiac impulses earlier than expected in the sequence of the baseline rhythm. The premature beat may originate in the atria, at the atrioventricular junction or in the ventricles and may reach other structures through different conduction patterns. The term describes an electrical phenomenon, not a prognosis: isolated premature beats in a healthy heart and ectopy associated with myocardial scar belong to different clinical settings, even though they may produce a similar sensation of an irregular heartbeat.

The patient may perceive the premature beat, the subsequent pause or the stronger contraction that follows. Symptom frequency and the actual number of events do not necessarily coincide. Assessment requires identification of the site, appropriate quantification, investigation of the substrate and correlation with symptoms. This page compares the different forms and their significance; the monographs on premature atrial contractions, premature junctional contractions and premature ventricular contractions address their specific features in detail.

Origin of the premature beat and interaction with sinus rhythm

Prematurity is defined relative to the expected cycle, not merely by the presence of a different morphology. A junctional or ventricular beat that appears after a pause may be a protective escape beat, whereas an impulse from the same site that occurs early is extrasystolic. This distinction prevents a necessary activation that supports the circulation from being treated as pathological ectopy. Sinus rhythm variability must also be considered when determining when the next beat would have been expected.

Premature impulses may result from abnormal automaticity, triggered activity or re-entry. Calcium overload, repolarization oscillations and tissue with heterogeneous conduction favor different mechanisms. The surface ECG often identifies the probable site but does not always demonstrate the cellular process. A stable morphology may indicate a repetitive origin without establishing whether the generator is automatic, triggered or part of a circuit.

A premature atrial contraction may conduct normally to the ventricles, conduct with aberrancy or be blocked. A junctional impulse may propagate independently toward the ventricles and atria; a ventricular impulse may conduct retrogradely and influence the sinus node. Retrograde conduction contributes to determining the timing of the next beat. The behavior of the pause therefore depends on the interaction among the ectopic generator, refractory tissue and the sinus pacemaker, not solely on the anatomical label assigned to the premature beat.

A full compensatory pause is traditionally associated with a ventricular impulse that does not alter the sinus cycle, but it is not an absolute criterion of origin. If the sinus node is reset, the pause may be incomplete; an interpolated beat may occur between two sinus activations without an obvious pause. Blocked premature atrial contractions or concealed junctional impulses may instead produce a long interval without a recognizable premature QRS. The full sequence is more informative than the isolated complex.

Mechanically, the premature beat may have reduced filling and generate a weak pulse. The following contraction may be more prominent because of greater filling and post-extrasystolic potentiation. Patients sometimes describe a "pause" followed by a thump, even though cardiac arrest has not occurred. This physiological explanation helps interpret the symptom, but it does not replace documentation when frequency, context or associated manifestations warrant further evaluation.

Electrocardiographic classification and description of ectopy

In premature atrial contractions, the premature P wave generally has a morphology different from the sinus P wave. It may deform the preceding T wave and be missed on rapid review. The QRS often remains narrow, but an early impulse may encounter a bundle branch that is still refractory and produce a wide complex. Absence of a QRS after a premature P wave indicates a blocked beat, which must be distinguished from failed conduction of a sinus P wave occurring at the expected time.

Premature junctional contractions may present with a retrograde P wave before or after the QRS, or with atrial activity hidden within the complex. Normal activation through the His-Purkinje system may produce a QRS similar to the baseline complex; aberrant conduction instead changes its appearance. A junctional origin cannot be established solely because a P wave is not visible, since overlap and signal quality may conceal an atrial impulse. In difficult cases, the conclusion may remain probabilistic.

In premature ventricular contractions, the complex is generally wide and has an activation sequence different from that of conducted rhythm. Morphology helps localize the site, but early involvement of the conduction system may produce relatively narrow complexes. Baseline bundle branch block makes comparison more difficult. Prematurity, atrial relationship, QRS morphology and repolarization must all be assessed, avoiding classification of every isolated wide beat as ventricular.

Bigeminy alternates a baseline beat with a premature beat; trigeminy and other patterns describe repetitive distributions. Couplets and sequences of multiple impulses require differentiation from brief tachycardias according to site and rate. Monomorphic ectopy and ectopy with multiple morphologies may suggest, respectively, a dominant origin or multiple sites, but changes in conduction may alter the appearance of the same impulse. Descriptive complexity is not an independent, universal measure of risk.

The coupling interval is the time between the preceding beat and the premature impulse. Very short coupling intervals may be important in particular ventricular phenotypes, especially when documented as a trigger of major arrhythmias. However, simply observing a beat during repolarization does not by itself predict cardiac arrest. Its relationship with the QT interval, ischemia, substrate and actually recorded arrhythmias determines whether the finding has a specific prognostic significance.

Causes, facilitating factors and clinical manifestations

Ectopy may occur in the absence of identifiable heart disease or may be associated with ischemia, inflammation, valvular heart disease, cardiomyopathies and chamber remodeling. Atrial ectopy may reflect atrial pressure and remodeling; ventricular ectopy may represent an idiopathic focus or a scar-related substrate. The finding does not by itself prove the presence of heart disease, but it may provide an opportunity to identify it through a diagnostic pathway proportionate to the clinical context.

Drugs, electrolytes and autonomic stimulation may modify the number of premature impulses. Potassium or magnesium imbalances, endocrine abnormalities, hypoxia and acute conditions warrant evaluation when plausible. Some drugs increase automaticity or alter repolarization; others may slow the baseline rhythm and make ectopy more apparent. Dose, interactions and renal function contribute to causal assessment and should not be separated from the temporal history of the episodes.

Insufficient sleep, stress and some exposures may be associated with palpitations, but the relationship should be individualized. Not every patient with ectopy needs indiscriminate elimination of caffeine or all activities that increase heart rate. Comparison among symptoms, the amount consumed and recordings may identify reproducible factors. Reducing a suspected exposure is different from attributing the entire phenomenon to it with certainty, especially when findings suggest heart disease.

Palpitations may be intense even with only a few premature beats, whereas a high burden may be almost asymptomatic. Body position, attention to the heartbeat and the intensity of the subsequent contraction influence perception. Dyspnea, chest pain, presyncope and syncope require more careful interpretation, without assuming that the observed premature beat is necessarily the cause. A hemodynamic disturbance or a more sustained arrhythmia may be present but not yet recorded.

Behavior during exercise and recovery may provide useful information, but it cannot be reduced to the rule that ectopy that disappears is always benign and ectopy that appears is always malignant. Morphology, burden, symptoms, ischemia and heart disease modify its significance. In some inherited phenotypes, the progressive appearance of ectopy during adrenergic stimulation requires a specific pathway; in other patients the phenomenon may be idiopathic. Exercise testing should answer a defined clinical question.

Investigations, quantification and assessment for heart disease

A twelve-lead ECG during ectopy is useful for defining site and morphology, whereas the baseline tracing may reveal abnormal conduction, pre-excitation, signs of scar or repolarization abnormalities. A single-lead recording may document the episode but provide less information about its origin. Artifacts and automated algorithms may confuse ectopy, aberrancy and noise; the diagnosis must be confirmed on clinically significant tracings.

Burden is the proportion of ectopic beats relative to the total number of beats analyzed in a recording. The value should be accompanied by recording duration, signal quality and temporal distribution. Ectopy varies from day to day, and a 24-hour Holter recording may not represent usual exposure. When quantification changes an important decision, longer or repeated recording may be useful to clarify a specific discrepancy without turning monitoring into serial testing without a clear objective.

Echocardiography assesses chamber size, ventricular function and valves. The presence of ventricular dysfunction with frequent ectopy requires differentiation between heart disease that generates premature beats and cardiomyopathy induced or worsened by ectopy. The two components often coexist. Cardiac magnetic resonance is particularly useful when morphology, history or function suggests scar, inflammation or a disease not well characterized by echocardiography, but it is not necessary for every occasional premature beat.

For ventricular ectopy, a burden around 10% or higher makes consideration of a related cardiomyopathy pertinent, with greater risk at higher burdens. The threshold is not an absolute biological boundary: many patients with a substantial burden maintain normal function, and other factors contribute to vulnerability. Demonstration of improvement after reduction of ectopy may support a causal relationship. These references should not be transferred automatically to atrial or junctional premature beats.

Blood tests, coronary assessment and genetic testing are reserved for relevant suspicions. A family history of sudden death, atypical ectopy or ectopy associated with syncope may require investigations different from those for an incidental finding. An electrophysiological study is useful when a mechanism needs to be clarified or a procedure planned, not to indiscriminately stratify all individuals with palpitations. Every test should alter a specific diagnostic, prognostic or therapeutic decision.

Prognostic significance and limitations of risk indicators

The risk associated with ectopy depends on site and substrate. Well-characterized idiopathic ectopy may have a favorable prognosis; the same numerical description in a patient with scar or cardiomyopathy has a different significance. The presence of couplets or multiple morphologies requires contextualization but does not automatically constitute an indication for a defibrillator. Risk stratification should use tools validated for any heart disease that has been identified.

A high atrial ectopic burden is associated in observational studies with a greater probability of atrial fibrillation and may signal an unfavorable atrial substrate. This association does not prove that every premature beat directly causes the outcome or that suppressing ectopy prevents stroke. Atrial ectopy alone is not an automatic indication for anticoagulation. It may instead justify attention to cardiovascular factors and targeted monitoring when the context makes as-yet undocumented atrial fibrillation plausible.

Ventricular ectopy may cause or worsen cardiomyopathy, but it may also be a marker of pre-existing disease. Morphology, site, QRS duration and temporal characteristics contribute alongside burden. Simply reducing the number of premature beats is therefore not the only goal: cardiac function, symptoms and treatment of the heart disease must also be assessed. In the presence of a documented trigger of ventricular fibrillation, management instead takes on the specific aim of preventing major recurrences.

Evidence from the CAST showed that pharmacological suppression of ventricular ectopy after myocardial infarction with certain antiarrhythmic drugs can increase mortality. This finding profoundly changed the relationship between an electrocardiographic endpoint and clinical benefit. It does not mean that every antiarrhythmic drug is harmful in every patient, but it prevents use of the number of premature beats as sufficient justification for prescribing a drug. Etiology, cardiac structure and drug safety are decisive elements.

The assessment must separate arrhythmic risk, symptoms and quality of life. A disorder with a favorable prognosis may be highly disabling and warrant treatment; poorly perceived ectopy may require surveillance when associated with dysfunction. Anxiety following a report may itself increase awareness of the beats. An accurate explanation of the significance of the finding contributes to care without replacing necessary investigations when warning signs are present.

Observation, pharmacological therapy and ablation

Clinical observation is appropriate for many patients with isolated ectopy, no heart disease and mild symptoms after adequate assessment. Management includes education, review of facilitating factors and follow-up instructions. An ECG completely free of premature beats is not required for management to be considered satisfactory. The decision to treat depends on symptoms, effects on function and risk associated with the mechanism, not simply on persistence of ectopy.

When necessary, pharmacological treatment is selected according to site and context. Beta-blockers or other drugs may reduce symptoms and burden in appropriate patients, but bradycardia, hypotension, conduction and ventricular function limit the options. More potent antiarrhythmic agents require stricter patient selection and safety monitoring. In concealed junctional forms, evidence may be limited to small series or individual cases and does not permit automatic application of protocols developed for ventricular ectopy.

Ablation may be indicated for selected symptomatic ventricular ectopy, related cardiomyopathy or documented arrhythmic triggers, with success rates and risks depending on the site. An origin near the conduction system or in structures that are difficult to access changes the balance. In atrial or junctional forms, the indication requires a precise clinical question and a favorable benefit-risk ratio. Simply finding a high number of premature beats does not mandate the same procedure in every patient.

Treatment of underlying heart disease continues independently of ectopy control. Ischemia, heart failure, inflammation or inherited disease may require measures that are not replaced by suppression of the focus. A defibrillator is considered according to the events and criteria of the specific condition, not solely because premature beats are present. Even after successful ablation, prognosis may continue to depend on the substrate and its evolution.

Follow-up assesses symptoms, cardiac function and ectopic burden when these elements can change management. A modest recurrence after a procedure does not necessarily imply clinical failure, whereas recurrence of dysfunction or major symptoms requires reassessment. The patient should know which signs warrant attention, especially syncope, new dyspnea and sustained palpitations. Success is measured by clinical benefit with adequate safety, not by erasing every irregularity from the tracing.